BioWorld

Phase III update Stokes hope; Dravet game-change Encoded?

Stoke Therapeutics Inc.’s speeded-up timeline for zorevunersen, the antisense oligonucleotide in development with Biogen Inc.

Encoded Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to ETX101 for the Treatment of Dravet Syndrome

Encoded Therapeutics, Inc. ("Encoded"), a clinical-stage biotechnology company developing precision genetic medicines for severe neurological disorders, today announced that the U.S. Food and Drug ...

Compressed data technique enables pangenomics at scale

Engineers at the University of California have developed a new data structure and compression technique that enables the ...
EDN

The high-speed data link to Mars faces a unique timing challenge

Experienced network designers know that the performance achievable of a data link depends on many factors, including the ...
Quanta Magazine

Distinct AI Models Seem To Converge On How They Encode Reality

Is the inside of a vision model at all like a language model? Researchers argue that as the models grow more powerful, they ...
Live Science on MSN

This new DNA storage system can fit 10 billion songs in a liter of liquid — but challenges remain for the unusual storage format

The new storage system could hold family photos, cultural artifacts and the master versions of digital artworks, movies, ...
IEEE

Data-Driven Architecture to Encode Information in the Kinematics of Robots and Artificial Avatars

Abstract: We present a data-driven control architecture designed to encode specific information, such as the presence or absence of an emotion, in the movements of an avatar or robot driven by a human ...
Yahoo Finance

Encoded Therapeutics Presents Positive Interim Efficacy Data from Initial Dose Levels of Phase 1/2 Trials Evaluating ETX101 Gene Therapy in Dravet Syndrome

SOUTH SAN FRANCISCO, Calif., December 05, 2025--(BUSINESS WIRE)--Encoded Therapeutics Inc., a clinical-stage biotechnology company developing genetic medicines for severe neurological disorders, today ...
Morningstar

Encoded Therapeutics to Present Interim Phase 1/2 Clinical Data on ETX101, the First One-time Gene Therapy in Development for Dravet Syndrome, at the 2025 American Epilepsy ...

Encoded Therapeutics to Present Interim Phase 1/2 Clinical Data on ETX101, the First One-time Gene Therapy in Development for Dravet Syndrome, at the 2025 American Epilepsy Society Annual Meeting – ...
Yahoo Finance

Encoded Therapeutics to Present Interim Phase 1/2 Clinical Data on ETX101, the First One-time Gene Therapy in Development for Dravet Syndrome, at the 2025 American Epilepsy ...

– Oral and poster presentations to include seizure and neurodevelopmental data from POLARIS Phase 1/2 Program that support advancement of ETX101 – SOUTH SAN FRANCISCO, Calif., December 01, ...
Morningstar

Clinical Proof-of-Concept Data for DNA-Encoded Monoclonal Antibodies (DMAbs) Published in Nature Medicine

Publication includes complete data for all participants (n=39) up to week 72, further demonstrating durable and tolerable expression of DMAbs Effective target binding and confirmed functional activity ...
BioSpace

Encoded Cuts 29% of Workforce to Extend Cash Runway, Advance Pipeline

Encoded’s layoffs will mostly affect its technology and early-stage research and development functions. The move is expected to keep the biotech operational well into 2026. To extend its cash runway ...